To assess if XBB.1.5 mRNA vaccines sufficiently protect patients with CLD against immune-evasive SARS-CoV-2 variants, we calculated the proportions of individuals who were lacking neutralization, as indicated by ACE2 binding inhibition of less than 20% (see methods section) [26]. Here, ACE2 is linked to congenital secretory chloride diarrhea 1.